Stock Scorecard



Stock Summary for Vaxcyte Inc (PCVX) - $85.96 as of 11/20/2024 8:34:40 PM EST

Total Score

9 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for PCVX

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for PCVX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for PCVX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for PCVX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for PCVX (50 out of 90)

Stock Price Rating (Max of 10) 9
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0

Latest News for for PCVX

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights 11/13/2024 9:30:00 PM
1 Vanguard ETF That Could Soar 27.1% Before the End of 2024, According to a Top Wall Street Analyst 11/10/2024 9:21:00 AM
Should iShares Russell 2000 ETF ( IWM ) Be on Your Investing Radar? 11/4/2024 11:20:00 AM
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML 11/1/2024 12:00:00 PM
1 Spectacular BlackRock ETF to Buy Ahead of the Russell 2000 Bull Market 10/31/2024 8:59:00 AM
Peering Into Vaxcyte's Recent Short Interest - Vaxcyte ( NASDAQ:PCVX ) 10/30/2024 7:30:00 PM
Should iShares Russell 2000 Growth ETF ( IWO ) Be on Your Investing Radar? 9/23/2024 10:20:00 AM
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 9/14/2024 7:00:00 AM
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference - Vaxcyte ( NASDAQ:PCVX ) 9/11/2024 8:05:00 PM
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference 9/11/2024 8:05:00 PM

Financial Details for PCVX

Company Overview

Ticker PCVX
Company Name Vaxcyte Inc
Country USA
Description Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally. The company is headquartered in Foster City, California.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 85.96
Price 4 Years Ago 26.57
Last Day Price Updated 11/20/2024 8:34:40 PM EST
Last Day Volume 1,714,802
Average Daily Volume 1,173,777
52-Week High 121.06
52-Week Low 48.24
Last Price to 52 Week Low 78.19%

Valuation Measures

Trailing PE N/A
Industry PE 120.49
Sector PE 40.32
5-Year Average PE -18.40
Free Cash Flow Ratio 4.91
Industry Free Cash Flow Ratio 15.59
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 17.88
Total Cash Per Share 17.49
Book Value Per Share Most Recent Quarter 27.47
Price to Book Ratio 3.17
Industry Price to Book Ratio 5.50
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 20.11
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 124,637,000
Market Capitalization 10,713,796,520
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -80.00%
Reported EPS 12 Trailing Months -4.58
Reported EPS Past Year -2.78
Reported EPS Prior Year -4.13
Net Income Twelve Trailing Months -507,648,000
Net Income Past Year -402,266,000
Net Income Prior Year -223,485,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 2,180,465,000
Total Cash Past Year 1,080,227,000
Total Cash Prior Year 931,376,000
Net Cash Position Most Recent Quarter 2,180,465,000
Net Cash Position Past Year 1,080,227,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 450,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 1,240,468,000
Total Stockholder Equity Prior Year 953,613,000
Total Stockholder Equity Most Recent Quarter 3,417,634,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -493,696,000
Free Cash Flow Per Share Twelve Trailing Months -3.96
Free Cash Flow Past Year -312,852,000
Free Cash Flow Prior Year -176,445,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -2.69
MACD Signal -1.36
20-Day Bollinger Lower Band 64.52
20-Day Bollinger Middle Band 96.76
20-Day Bollinger Upper Band 128.99
Beta 1.01
RSI 36.22
50-Day SMA 78.90
150-Day SMA 50.75
200-Day SMA 43.83

System

Modified 11/19/2024 9:52:14 AM EST